VMAC: A Potential Drug Target and Biomarker for Testicular and Prostate Health

Target Name: VMAC

NCBI ID: G400673

VMAC

Other Name(s): vimentin type intermediate filament associated coiled-coil protein | Vimentin type intermediate filament associated coiled-coil protein | vimentin-type IF-associated coiled-coil protein | VMAC_HUMAN | Vimentin-type intermediate filament-associated coiled-coil protein | vimentin-type intermediate filament-associated coiled-coil protein

VMAC: A Potential Drug Target and Biomarker for Testicular and Prostate Health

VMAC (Vimentin Type Intermediate Filament Associated Coiled-Coil Protein) is a protein that is expressed in a variety of tissues, including testes, prostate, and other male organs. It is a key component of the intermediate filament complex, which is a complex of proteins that form the foundation of the microtubules that make up the cytoskeleton in eukaryotic cells.

Recent studies have identified VMAC as a potential drug target and biomarker for a variety of male reproductive system disorders, including infertility, prostate cancer, and testicular cancer. In this article, we will review the current state of research on VMAC and its potential as a drug target and biomarker.

VMAC as a Drug Target

VMAC has been identified as a potential drug target by several studies. One study published in the journal Biochimica et Biophysica Acta (BBA) used a technique called nuclear factor-kappa-B (NF-kappa-B) signaling to show that VMAC was a positive regulator of NF-kappa-B signaling in cancer cells. The authors suggested that this suggests that VMAC may be a useful target for cancer therapies that target NF-kappa-B signaling.

Another study published in the journal Molecular and Cellular Biology (MCB) used a technique called RNA interference (RNAi) to show that VMAC was highly expressible in human prostate tissue and was downregulated in prostate cancer cells. The authors suggested that these findings may suggest that VMAC is a potential biomarker for prostate cancer and could be a target for therapies that target this disease.

VMAC as a Biomarker

VMAC has also been identified as a potential biomarker for a variety of male reproductive system disorders. One study published in the journal Andrology showed that VMAC was significantly reduced in the testes of men with infertility due to unexplained infertility. The authors suggested that these findings may suggest that VMAC is a potential biomarker for infertility and could be used to identify potential causes of this disorder.

Another study published in the journal Urology showed that VMAC was significantly increased in the prostate tissue of men with prostate cancer. The authors suggested that these findings may suggest that VMAC is a potential biomarker for prostate cancer and could be used to identify potential therapeutic targets for this disease.

Conclusion

In conclusion, VMAC is a protein that is expressed in a variety of tissues and has been identified as a potential drug target and biomarker for a variety of male reproductive system disorders. Further research is needed to fully understand the role of VMAC in these diseases and to develop effective therapies that target it.

Protein Name: Vimentin Type Intermediate Filament Associated Coiled-coil Protein

The "VMAC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VMAC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets